Edition:
United Kingdom

Profile: Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

2.74USD
18 Apr 2019
Change (% chg)

$-0.08 (-2.84%)
Prev Close
$2.82
Open
$2.80
Day's High
$2.80
Day's Low
$2.66
Volume
103,669
Avg. Vol
224,541
52-wk High
$36.25
52-wk Low
$1.70

Altimmune, Inc., formerly Pharmathene, Inc., incorporated on April 25, 2005, is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies, RespirVec and Densigen. Its candidates include NasoVAX, HepTcell, NasoShield and Oncosyn.

NasoVAX

NasoVAX is an intranasally administered recombinant influenza vaccine, which uses an adenovector to achieve expression of the influenza antigen in the target cell, thereby potentially stimulating a broader and more rapid immune response than traditional influenza vaccines. The Company has completed Phase I clinical trials of NasoVAX.

HepTcell

HepTcell is being tested as an immunotherapy for patients chronically infected with the hepatitis B virus (HBV). HepTcell is in Phase I clinical testing.

NasoShield

NasoShield is an intranasal, single-dose anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. NasoShield is in pre-clinical stage.

Oncosyn

Oncosyn is being developed as a cancer immunotherapeutic product candidate. Oncosyn targets multiple tumor antigens simultaneous to prevent tumor escape. Oncosyn is in pre-clinical stage.

Company Address

Altimmune Inc

910 Clopper Rd Ste 201S
GAITHERSBURG   MD   20878-1361
P: +1240.6541450
F: +1302.6745266

Company Web Links